3ROMANO M, LESCH CA, MEISE KS, et al. Increased gastroduodenal concentrations of transforming growth factor alpha in adaptation to aspirin in monkeys and rats [J]. Gastrcenterology,1996, 110(5): 1448-1455.
4SCHOENFELD P, KIMMEY MB, SCHEIMAN J, et al. Review article: nonsteroidal anti-inflammatory drug-associated gastrointestinal complications-guidelines for prevention and treatment [J].Aliment Pharmacol Ther, 1999, 13(10): 1273-1285.
5LANAS A, Nonsteroidal anti-inflammatory drugs,low-dose aspirin,and potential ways of reducing the risk of complications[J]. Eur J Gastroenterol Hepatol, 2001, 13(6): 623-626.
6KELLY JP, KAUFMAN DW, JURGELON JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated nr buffered product [J]. Lancet, 1996, 384 (9039):1413-1416.
7[1]Silverstein FE, Grahan DY, Senior JR. Davies HW, Struthers BJ, Bittman RM, Misoprostol reduces serious gastrintestinal complicstions patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med,1999;123(4);241-249
8[2]Bensen WG, Zhao SZ, Burke TA, et al. Upper gastrointestinal tolerability of celecoxit,a COX-2 specific inhibitor,compared to naproxen and placebo.J Rheumatol,2000,27(7):1876-1883
9[3]Bombardier C. An evidence-based evaluation of the gastrointestinal safety of coxibs.Am J Cardiol,2002,89(1):3-9
